Research
Molecular
Inhibiting the Group-specific component (GC) gene may provide a novel therapeutic target for treating metabolic diseases.
Practitioners may consider exploring GC inhibition as a treatment option for metabolic diseases.
StrongSupportsmedium confidence
GC therefore represents a promising novel therapeutic target for metabolic diseases.
Why this rating
The claim is supported by studies of GC-null humans and mice, indicating safety and potential benefits.
Source
On the potential of group-specific component (GC) inhibition for treating metabolic disease
Richard Gill et al. · Metabolism and Target Organ Damage · 2026
review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →